Sherrie Gould
Nurse Practitioner · la Jolla, CANPI 1154467975
Payments from drug & device makers
Across 966 payments — averaging $263.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$117K
- Neurocrine Biosciences, Inc.$46K
- Amneal Pharmaceuticals LLC$16K
- Medtronic$15K
- AbbVie$14K
- Boston Scientific$11K
- plus $37K from 28 others
What the payments were for
- Consulting fees$35,40014%
- Speaking & faculty fees$147,87358%
- Travel & lodging$45,06818%
- Food & beverage$24,0509%
- Education$2,4411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 296 | $116,535 |
| Neurocrine Biosciences, Inc. | 90 | $45,769 |
| Amneal Pharmaceuticals LLC | 62 | $16,218 |
| Medtronic | 122 | $14,636 |
| AbbVie(2 entities) | 114 | $14,219 |
| Boston Scientific | 47 | $10,853 |
| MDD US Operations, LLC | 60 | $10,408 |
| Merz Pharmaceuticals, LLC | 24 | $8,037 |
| Abbott | 43 | $6,264 |
| Kyowa Kirin, Inc. | 28 | $3,885 |
| Tanabe Pharma America, Inc. | 7 | $2,785 |
| Acorda Therapeutics, Inc | 12 | $1,494 |
| Adamas Pharmaceuticals, Inc. | 8 | $1,176 |
| Sunovion Pharmaceuticals Inc. | 9 | $962 |
| AstraZeneca(2 entities) | 4 | $315 |
| Teva Pharmaceuticals USA, Inc. | 8 | $254 |
| Lundbeck LLC | 6 | $164 |
| Jazz Pharmaceuticals Inc. | 1 | $141 |
| Incyte Corporation | 1 | $116 |
| Neurelis, Inc. | 1 | $105 |
| Novartis | 4 | $91 |
| Supernus Pharmaceuticals, Inc. | 3 | $77 |
| Amgen(2 entities) | 3 | $53 |
| GE HealthCare | 2 | $49 |
| SK Life Science, Inc. | 2 | $33 |
| UCB, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Impel Pharmaceuticals LLC | 1 | $23 |
| TG Therapeutics, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Clearpoint Neuro, Inc. | 1 | $17 |
| Corium, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$112,621
- INGREZZA$32,793
- ONGENTYS$12,409
- Duopa$11,611
- PERCEPT PC BRAINSENSE$9,213
- GOCOVRI$8,720
- INBRIJA$7,780
- VERCISE$6,859
- RYTARY$5,365
- CREXONT$5,138
- INFINITY$4,354
- NOURIANZ$3,427
- GENERAL DBS$1,215
- ONGENTYS 50MG CAPSULES 30$932
- KYNMOBI$829
- SenSight$448
- INTELLIS ADAPTIVESTIM$439
- XEOMIN$359
- VYALEV$225
- PROCLAIM$160
How this compares
$254,831 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 307 | $2,073,366 |
| RytaryCarbidopa/Levodopa | 689 | $830,779 |
| GocovriAmantadine Hcl | 87 | $336,869 |
| OngentysOpicapone | 84 | $116,748 |
| IngrezzaValbenazine Tosylate | 13 | $104,721 |
| Rasagiline Mesylate | 175 | $43,040 |
| NeuproRotigotine | 24 | $34,348 |
| LinzessLinaclotide | 32 | $30,319 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 628 | $27,661 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 72 | $25,854 |
| NourianzIstradefylline | 12 | $22,089 |
| MyrbetriqMirabegron | 23 | $19,806 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 146 | $14,220 |
| Pramipexole ErPramipexole Di-Hcl | 12 | $13,035 |
| Selegiline Hcl | 44 | $6,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $116,535 | $2,073,366307 claims |
| Amneal Pharmaceuticals LLCRytary | $16,218 | $830,779689 claims |
| MDD US Operations, LLCGocovri | $10,408 | $336,86987 claims |
| Neurocrine Biosciences, Inc.Ongentys, Ingrezza | $45,769 | $221,46997 claims |
| UCB, Inc.Neupro | $24 | $34,34824 claims |
| AbbVieLinzess | $14,219 | $30,31932 claims |
| Kyowa Kirin, Inc.Nourianz | $3,885 | $22,08912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in la Jolla
- Katie Bordonarola Jolla$48K
- Stephanie Yoakumla Jolla$29K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.